Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

lymphoma

438 clinical trials

453 products

72 drugs

Product
DZ-002
Clinical trial
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas - INSTAL-101
Status: Terminated, Estimated PCD: 2022-07-26
Product
Ulevostinag
Product
Pembrolizumab
Product
E7766
Product
AZD3470
Clinical trial
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-04-16
Product
CPI-0209
Product
Zimberelimab
Clinical trial
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
AB308
Clinical trial
Phase 1 Open-label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Status: Completed, Estimated PCD: 2022-04-21
Product
REVLIMID®
Clinical trial
Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea
Status: Completed, Estimated PCD: 2023-08-15
Product
parsaclisib
Clinical trial
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Status: Completed, Estimated PCD: 2021-09-24
Product
Glofitamab
Clinical trial
A Phase I, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Glofitamab as Single Agent Administered After a Fixed, Single Dose Pretreatment of Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-10-25
Product
Lisocabtagene maraleucel
Product
Tocilizumab
Clinical trial
A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
Status: Recruiting, Estimated PCD: 2024-12-30
Product
SG2501
Product
[14C]SHR2554
Clinical trial
Phase I Clinical Trial of Substance Balance of [14C]SHR2554 in Healthy Chinese Subjects
Status: Completed, Estimated PCD: 2023-11-27
Clinical trial
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Status: Active (not recruiting), Estimated PCD: 2021-01-15
Clinical trial
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)
Status: Recruiting, Estimated PCD: 2024-02-29
Clinical trial
A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Status: Completed, Estimated PCD: 2023-02-16
Product
Fadraciclib
Product
HG146
Product
PD-(L)1 antibody
Clinical trial
A Phase I Open Label Study of HG146 Alone /in Combination With PD-(L)1 Inhibitor Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors or Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas.
Status: Recruiting, Estimated PCD: 2027-07-30
Product
GRC 54276
Product
GRC 54276 + Pembrolizumab
Product
Single Arm
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2026-04-30
Product
CD19-targeted Chimeric Antigen Receptor T Cells
Clinical trial
An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed and Refractory (R/R) LBCL
Status: Recruiting, Estimated PCD: 2024-04-30
Product
Abexinostat
Product
ONM-501
Product
Cemiplimab
Clinical trial
A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
Status: Completed, Estimated PCD: 2023-12-15
Product
JCAR017
Clinical trial
First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Parsaclisib
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-10-28
Product
Placebo
Clinical trial
An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Status: Completed, Estimated PCD: 2023-04-25
Product
Surufatinib
Product
Acalabrutinib
Product
Bendamustine
Product
Rituximab
Clinical trial
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Pirtobrutinib
Product
Entrectinib
Product
Obinutuzumab
Clinical trial
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Status: Terminated, Estimated PCD: 2023-11-22
Product
Tazemetostat
Product
Ibrutinib
Product
Zanubrutinib
Clinical trial
A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
Status: Recruiting, Estimated PCD: 2028-03-31
Product
TAK-981
Clinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Status: Recruiting, Estimated PCD: 2024-12-07
Product
Ponatinib
Product
CAN2109
Clinical trial
A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors or Lymphomas.
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Cyclophosphamide
Product
CB-010
Product
Fludarabine
Clinical trial
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Zilovertamab Vedotin
Clinical trial
A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)
Status: Recruiting, Estimated PCD: 2026-01-26
Product
BMF-219
Product
Nemtabrutinib
Product
HMPL-689
Clinical trial
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 Alone and in Combination With Rituximab to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Relapsed/Refractory CD20 Positive B-cell Non-Hodgkin's Lymphoma (NHL)
Status: Recruiting, Estimated PCD: 2024-10-01
Product
BYON4228
Product
CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
Product
CC-90010
Clinical trial
A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Safety of 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma Previously Treated With External Beam Radiation Therapy
Status: Withdrawn, Estimated PCD: 2026-03-01
Product
Maplirpacept
Product
Remitoro
Clinical trial
Post-marketing Observational Study of Remitoro® Intravenous Injection 300 μg - Safety of Remitoro in Patients With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TTI-622 (PF-07901801), A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED OR REFRACTORY LYMPHOMA
Status: Active (not recruiting), Estimated PCD: 2024-07-10
Product
BYON4228 + Rituximab
Clinical trial
A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (KEYNOTE-A33)
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status: Terminated, Estimated PCD: 2023-12-12
Product
CC-292
Product
CC-122
Product
CC-223
Product
ALPN-202
Clinical trial
An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)
Status: Terminated, Estimated PCD: 2022-11-08
Clinical trial
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Prednisone
Product
Zilovertamab
Product
Brentuximab Vedotin
Product
Doxorubicin
Product
NKX019
Product
GRC 54276 + Atezolizumab
Clinical trial
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Prednisolone
Product
JNJ-87801493
Product
JNJ-80948543
Product
JNJ-75348780
Clinical trial
A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Status: Recruiting, Estimated PCD: 2026-07-08
Clinical trial
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-10
Product
CC-99282
Clinical trial
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-09-07
Product
CC-220
Product
Vincristine
Product
Polatuzumab vedotin
Product
Dexamethasone
Clinical trial
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Product
DS-3201b
Product
CFT7455
Product
QLF31907
Clinical trial
An Open, Dose-escalating Phase Ia Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLF31907 Injection in Patients With Advanced Cancer
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Status: Recruiting, Estimated PCD: 2027-10-25
Product
CC-90011
Product
Rituximab Biosimilar
Clinical trial
A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Status: Terminated, Estimated PCD: 2024-03-25
Product
Rifampicin
Product
Itraconazole
Clinical trial
A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LB1410, A Recombinant Anti-PD-1 and Anti-TIM-3 Humanized Bispecific Antibody for Injection in Patients With Advanced Solid Tumors or Lymphoma（Keyplus-001）
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Status: Completed, Estimated PCD: 2022-10-07
Product
RO7443904
Product
LB1410
Product
Lymphodepleting
Clinical trial
A Phase 1/2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL).
Status: Completed, Estimated PCD: 2024-01-26
Product
IMC-002
Clinical trial
An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Durvalumab
Clinical trial
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
Status: Completed, Estimated PCD: 2023-02-15
Product
Relatlimab
Product
Nivolumab
Clinical trial
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection (Anti LAG-3 Monoclonal Antibody) in Patients With Advanced/Metastatic Solid Tumor or Lymphoma
Status: Completed, Estimated PCD: 2023-08-18
Product
HLX26
Clinical trial
A Phase Ib Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Patients With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-19
Product
Polatuzumab Vedotin
Product
Venetoclax
Product
STP938
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-03-06
Product
Vorinostat
Clinical trial
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2012-04-01
Clinical trial
A Phase 1 Study of JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Chemotherapy
Product
Oral repotrectinib
Clinical trial
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma
Status: Completed, Estimated PCD: 2017-12-20
Product
CPI-0610
Clinical trial
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Status: Recruiting, Estimated PCD: 2026-04-17
Clinical trial
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-12-31
Product
ADI-001
Product
Valemetostat
Product
Tafasitamab
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety of SGN-35T in Adults With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2027-06-30
Product
SGN-35T
Product
Recombinant Humanized Anti-CD52 Monoclonal Antibody
Clinical trial
A A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Recruiting, Estimated PCD: 2024-11-30
Product
BGB-11417
Clinical trial
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
Status: , Estimated PCD: 2024-11-01
Clinical trial
An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Completed, Estimated PCD: 2020-06-16
Product
MT-101
Clinical trial
A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Status: Completed, Estimated PCD: 2023-05-03
Clinical trial
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Status: Completed
Clinical trial
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-08-20
Product
CC-96673
Clinical trial
A Phase 1B, Multicenter, Open-label Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Product
RPTR-147
Clinical trial
A Phase 1/2 Study of Deep IL-15 Loaded T-Cells Alone and in Combination With Pembrolizumab in Patients With Select Solid Tumors and Lymphomas
Status: Terminated, Estimated PCD: 2022-09-07
Clinical trial
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Terminated, Estimated PCD: 2019-06-10
Product
JS014
Product
PNT2258
Product
FT500
Product
Epcoritamab
Product
SEA-CD40
Product
Temsirolimus
Clinical trial
STAR-TOR- REGISTRY FOR THE EVALUATION OF THE SAFETY, TOLERABILITY AND EFFICACY OF TEMSIROLIMUS (TORISEL), SUNITINIB (SUTENT) AND AXITINIB (INLYTA) FOR THE TREATMENT OF SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA (MRCC), MANTLE CELL LYMPHOMA (MCL) AND GASTRO-INTESTINAL STROMA TUMOR (GIST).
Status: Completed, Estimated PCD: 2021-12-28
Product
Sunitinib
Clinical trial
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Status: Completed, Estimated PCD: 2022-11-15
Product
LOXO-338
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Status: Withdrawn, Estimated PCD: 2026-11-01
Product
MK-2118
Clinical trial
A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Status: Completed, Estimated PCD: 2023-02-22
Clinical trial
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2021-06-11
Product
Carboplatin
Clinical trial
Expanded Access to Epcoritamab
Status:
Product
T3011
Product
Naloxone Hydrochloride
Clinical trial
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Status: Terminated, Estimated PCD: 2022-09-01
Clinical trial
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2023-05-09
Product
PU-AD
Product
Ibritumomab tiuxetan
Clinical trial
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2016-07-11
Product
Lenalidomide
Clinical trial
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma
Status: Completed, Estimated PCD: 2018-06-22
Product
Brentuximab vedotin
Clinical trial
Phase 1/Phase 2 Study of Sequential Chimeric Antigen Receptor T Cell Targeting at CD19 and CD22 B-cell Antigens Treating Refractory or Relapsed B-cell Lymphoma Patients
Status: Not yet recruiting, Estimated PCD: 2024-12-10
Clinical trial
A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intravenously in Patients With Advanced Solid Tumors.
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2023-04-10
Clinical trial
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Status: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2021-10-21
Product
Ifosfamide
Product
Etoposide
Product
Idarubicin
Clinical trial
A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2018-12-19
Product
LOXO-305
Product
DZD8586
Clinical trial
A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-05-04
Product
Sepantronium Bromide
Product
Ixazomib
Product
BMS-986403
Product
TTX-030
Clinical trial
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
Recombinant Humanized Anti-CD52 Monoclonal Antibody in the Treatment of Relapsed and Refractory NHL and Initially Treated T-PLL Phase I Clinical Study on Safety and Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy
Status: , Estimated PCD: 2022-12-30
Product
Epacadostat
Product
Nab Paclitaxel
Clinical trial
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.
Status: Active (not recruiting), Estimated PCD: 2023-03-28
Clinical trial
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
CD19 and CD22 targeted CAR-T cells
Clinical trial
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Terminated, Estimated PCD: 2023-05-04
Product
Atezolizumab
Product
IL-2
Product
Gemcitabine
Product
CS1003
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Status: Terminated, Estimated PCD: 2021-07-12
Clinical trial
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2023-04-26
Clinical trial
Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
Status:
Product
GZ17-6.02
Product
Capecitabine
Product
Axitinib
Product
FT596
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Terminated, Estimated PCD: 2023-09-27
Product
TAK-659
Clinical trial
A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2021-08-03
Clinical trial
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Product
Relmacabtagene Autoleucel
Product
Azacitidine
Product
Carfilzomib
Clinical trial
A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-09-11
Clinical trial
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-09-10
Clinical trial
A Phase IIa, Multi-center, Dose-finding Study to Evaluate Safety and Efficacy for Prevention of Oral Mucositis and PK of MIT-001 in Patients With Lymphoma or Multiple Myeloma Receiving Conditioning Chemotherapy Followed by Auto HSCT
Status: Recruiting, Estimated PCD: 2023-10-31
Clinical trial
A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Nab-paclitaxel
Clinical trial
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Anti-CD20 Targeting agent
Product
Isatuximab
Clinical trial
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Product
resminostat
Clinical trial
A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study
Status: Active (not recruiting), Estimated PCD: 2023-03-01
Product
Copanlisib
Clinical trial
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Terminated, Estimated PCD: 2023-09-15
Product
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Product
CD19 CAR-T cells
Product
IPH4102
Clinical trial
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2019-03-15
Clinical trial
A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Product
NiCord
Clinical trial
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)
Status: Terminated, Estimated PCD: 2022-11-09
Product
COVID-19 Vaccine
Product
MIT-001
Product
Normal Saline
Clinical trial
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Status: Terminated, Estimated PCD: 2020-06-01
Clinical trial
Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
Status: Recruiting, Estimated PCD: 2023-01-26
Product
vincristine
Product
CAR-T Autologous T cell
Clinical trial
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-09-06
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
An Open-Label, Multicenter, Dose-Escalation and Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KN046 Monotherapy in Subjects With Advanced Solid Tumors and Lymphoma
Status: Completed, Estimated PCD: 2023-01-03
Product
lenalidomide
Product
BPX-501
Product
Rimiducid
Clinical trial
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2021-04-29
Clinical trial
A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Patients With Locally Advanced/Metastatic Solid Tumors or Lymphoma
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)
Status: Terminated, Estimated PCD: 2016-11-01
Product
prednisone
Product
HLX301
Product
KN046
Product
IPI-145
Product
CAR-T
Clinical trial
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2019-05-27
Clinical trial
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-04-24
Product
T-1301
Clinical trial
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Status: Not yet recruiting, Estimated PCD: 2027-04-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Status: Completed, Estimated PCD: 2022-05-30
Clinical trial
A Phase I Study of Safety, Tolerability and Pharmacokinetics of T-1301 Capsules in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Product
FT819
Clinical trial
A Phase I Study of FT819 in Subjects With B-cell Malignancies
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2016-08-01
Clinical trial
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I Study on Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of LP-118 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96)
Status: Completed, Estimated PCD: 2005-06-01
Product
PCI-32765
Product
HSPPC-96
Product
Keynatinib
Clinical trial
An Exploratory Clinical Study of Keynatinib in Relapsed/Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-10-10
Clinical trial
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
Status: Not yet recruiting, Estimated PCD: 2038-12-31
Clinical trial
Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies
Status:
Product
tabelecleucel
Clinical trial
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Status: Active (not recruiting), Estimated PCD: 2021-02-26
Clinical trial
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Status:
Product
LP-118
Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Status: Terminated, Estimated PCD: 2022-05-16
Clinical trial
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Status: Completed, Estimated PCD: 2023-09-22
Product
Alectinib
Clinical trial
ISTODAX® for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Istodax
Product
CD19 and CD22 Targeted CAR-T Cells
Product
OSE-279
Clinical trial
A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas
Status: Recruiting, Estimated PCD: 2024-05-01
Product
rivogenlecleucel
Clinical trial
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Completed, Estimated PCD: 2022-10-26
Clinical trial
A Phase 1b Study of TAK-659 in Combination With NKTR-214 in Patients With Advanced Non-Hodgkin Lymphoma
Status: Withdrawn, Estimated PCD: 2021-11-10
Product
NKTR-214
Clinical trial
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Withdrawn, Estimated PCD: 2019-01-14
Product
SyB L-0501RI
Clinical trial
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Status: Completed, Estimated PCD: 2016-06-22
Clinical trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Status: , Estimated PCD: 2027-07-02
Clinical trial
A Multicenter, Open-label, Phase I/II Study to Investigate the Safety and Tolerability of SyB L-0501RI (Bendamustine Hydrochloride for Injection) Administered As an Intravenous (IV) Rapid Infusion Over 10 Minutes
Status: Completed, Estimated PCD: 2020-09-09
Product
VP301
Clinical trial
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Status: Terminated, Estimated PCD: 2020-06-30
Clinical trial
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status: Completed, Estimated PCD: 2022-03-23
Product
Sym022
Clinical trial
An Open-Label Phase 1/2 Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-06-06
Product
ibrutinib
Product
itacitinib
Clinical trial
A Phase 1b, Open-Label, Dose-Escalation Study for the Safety, Tolerability, and Pharmacokinetics of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Status: Completed, Estimated PCD: 2020-05-05
Clinical trial
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Status: Completed, Estimated PCD: 2023-01-10
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
Status: Terminated, Estimated PCD: 2023-06-19
Product
TJ011133
Product
Sym021
Product
Sym023
Clinical trial
A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma
Status: Terminated, Estimated PCD: 2022-11-08
Clinical trial
A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).
Status: Completed, Estimated PCD: 2023-10-23
Clinical trial
A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma
Status: Completed, Estimated PCD: 2022-05-23
Product
Diphenhydramine
Product
Standard of Care
Product
Paracetamol
Clinical trial
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Status: Terminated, Estimated PCD: 2021-06-18
Clinical trial
A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2020-08-17
Clinical trial
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2028-09-28
Product
AZD0466
Clinical trial
A Phase 1b Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
PEP07
Clinical trial
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2018-06-01
Product
ASN002
Product
LAM-002A
Clinical trial
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2020-03-09
Product
Lisocabtagene Maraleucel
Clinical trial
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
Status: Completed, Estimated PCD: 2019-03-06
Clinical trial
LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2025-05-01
Product
BAFF CAR-T
Clinical trial
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Status: Active (not recruiting), Estimated PCD: 2009-11-11
Drug
Filgrastim
Product
Busulfan
Drug
cyclophosphamide
Product
Cyclosporine
Drug
Melphalan
Product
Mycophenolate Mofetil
Clinical trial
Evaluation of Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Oncologic and Hematologic Patients
Status: Completed, Estimated PCD: 2010-05-01
Product
NYMC X-179A
Clinical trial
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Status: Not yet recruiting, Estimated PCD: 2026-11-23
Product
Golcadomide
Drug
Varlilumab
Drug
Vincristine
Clinical trial
Phase II Study of Concurrent Tislelizumab and Radiotherapy for Treatment-naïve, Newly Diagnosed Low-risk Extranodal NK/T-cell Lymphoma, Nasal Type
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Tislelizumab
Clinical trial
Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2005-11-01
Drug
rituximab
Clinical trial
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2023-10-02
Product
LMP744
Clinical trial
A Single-arm, Open-label Clinical Study to Assess the Safety and Efficacy of the C752 CAR-T Cells for Patients With CD19+ Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-24
Product
C752
Clinical trial
Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
Status: Active (not recruiting), Estimated PCD: 2020-12-30
Product
R-CHOP
Clinical trial
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-09-15
Product
Polatuzumab
Clinical trial
Pilot Trial for Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy
Status: Completed, Estimated PCD: 2002-03-01
Product
Id-KLH
Clinical trial
Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL
Status: Recruiting, Estimated PCD: 2024-08-20
Product
R-CHOP Protocol
Clinical trial
Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Kappa CD28 T cells
Clinical trial
A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2005-11-01
Drug
carmustine
Drug
cytarabine
Drug
etoposide
Product
melphalan
Clinical trial
Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
EBV-specific T cells
Clinical trial
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine
Status: Completed, Estimated PCD: 2023-05-25
Product
mRNA-1273
Clinical trial
A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2016-08-25
Drug
bortezomib
Clinical trial
Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)
Status: Active (not recruiting), Estimated PCD: 2026-01-31
Product
SGN-35
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan
Status: Completed, Estimated PCD: 2019-05-30
Drug
sirolimus
Drug
tacrolimus
Clinical trial
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release
Status:
Clinical trial
CD19-directed CAR-T Cell Therapy for Refractory or Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma: a Multicenter Phase I/II Trial.
Status: Not yet recruiting, Estimated PCD: 2028-10-01
Drug
Tisagenlecleucel
Clinical trial
An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status: Terminated, Estimated PCD: 2023-05-26
Product
Mocetinostat
Clinical trial
Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]
Status: , Estimated PCD: 1998-10-01
Product
Bleomycin
Product
Mechlorethamine
Drug
prednisone
Product
Procarbazine
Product
Vinblastine
Clinical trial
PH-139: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Status: , Estimated PCD: 2026-06-30
Product
Gamitrinib
Clinical trial
A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP
Status: Terminated, Estimated PCD: 2023-04-20
Product
AG-270
Clinical trial
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation
Status: Completed, Estimated PCD: 2023-09-01
Product
BEAM
Product
CEM protocol
Clinical trial
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Anti Cluster of Differentiation Antigen 19 (Anti-CD19) Chimeric Antigen Receptor T (CAR T) Cell Therapy With Kymriah/tIsagenlecleucel (LOKI)
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
BEAM + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2014-11-01
Drug
docetaxel
Drug
Abraxane
Product
gemcitabine
Clinical trial
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Status: Completed, Estimated PCD: 2023-12-20
Product
T cells (Tcon) and Regulatory T cells (Treg)
Clinical trial
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Status: Completed, Estimated PCD: 2022-10-22
Clinical trial
A Single-center, Non-interventionary Clinical Study Evaluating the Efficacy and Safety of Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
Status: Active (not recruiting), Estimated PCD: 2023-12-19
Product
immunochemotherapies
Clinical trial
A Comparative Study of Retrospective Outcomes Including Efficacy of Therapy Between Advanced Immunotherapy and Classical Immunochemotherapy in Relapsed/Refractory Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
PD-1 antibody
Clinical trial
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2017-06-21
Product
LMP400
Product
LMP776
Clinical trial
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
Treatment Arm A
Clinical trial
Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-07-15
Drug
obinutuzumab
Drug
lenalidomide
Drug
ibrutinib
Drug
venetoclax
Clinical trial
A Phase 1, Open-label Study to Evaluate SGN-35C in Adults With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2028-02-28
Product
SGN-35C
Clinical trial
Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment
Status: Terminated, Estimated PCD: 2021-03-11
Drug
Atezolizumab
Clinical trial
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Palbociclib
Product
Trastuzumab + Pertuzumab
Product
Vemurafenib + Cobimetinib
Clinical trial
Natural Killer Cell Selected T-cell Depleted Donor Lymphocyte Infusions (NK-DLI) in Patients After HLA-haploidentical Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2011-03-01
Product
CD3-depleted/CD56+ selected natural killer cells
Drug
Regorafenib
Product
Olaparib
Product
Nivolumab and Ipilimumab
Product
Abemaciclib
Product
Talazoparib
Product
Atezolizumab and Talazoparib
Drug
Entrectinib
Drug
Larotrectinib
Clinical trial
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2013-09-01
Clinical trial
A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2000-12-01
Product
CHOP
Clinical trial
Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Drug
Gemcitabine
Clinical trial
Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells
Clinical trial
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Status: , Estimated PCD: 2024-12-01
Product
Glucarpidase
Clinical trial
Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients With Lymphoma Undergoing Autologous Stem Cell Harvest
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Eltrombopag olamine
Clinical trial
A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
Status: Active (not recruiting), Estimated PCD: 2023-01-25
Product
R2-MANT
Product
R-MANT
Clinical trial
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Recruiting, Estimated PCD: 2024-01-15
Clinical trial
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2001-02-01
Product
filgrastim
Drug
pegfilgrastim
Product
cisplatin
Drug
etoposide
Product
methylprednisolone
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-09-13
Product
CD19- and CD22 specific CAR
Clinical trial
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Status: Recruiting, Estimated PCD: 2029-09-01
Product
Balstilimab
Clinical trial
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Status: Not yet recruiting, Estimated PCD: 2030-07-01
Drug
fludarabine
Product
CD70-CAR T cell infusion
Product
Mesna
Product
Tucatinib plus Trastuzumab Subcutaneous
Product
Futibatinib
Clinical trial
Phase I/II Study of Pembrolizumab and In-situ Injection of CMP-001 in Patients With Relapsed and Refractory Lymphomas
Status: , Estimated PCD: 2025-04-01
Product
CMP-001
Clinical trial
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Status: Recruiting, Estimated PCD: 2024-09-10
Product
Fecal Microbiota Transplantation
Clinical trial
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Triamcinolone
Product
Bexarotene
Product
Nitrogen Mustard
Clinical trial
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Status: Recruiting, Estimated PCD: 2026-01-30
Product
Loncastuximab Tesirine
Clinical trial
Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-09-30
Product
ATLCAR.CD30.CCR4
Clinical trial
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2027-07-01
Product
CD19/CD22-CAR-transduced T cells
Clinical trial
Value of Chemokine Receptor CXCR4-targeting Molecular Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Status: Recruiting, Estimated PCD: 2024-12-01
Product
68Ga-Pentixafor
Clinical trial
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Pilot Feasibility Trial of Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Magnesium Chloride
Product
Post-Transplant Cyclophosphamide
Product
Tacrolimus
Clinical trial
Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2024-01-22
Product
BR-I
Clinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
CD19/CD22 CAR T-Cells
Clinical trial
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination With JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-07-11
Product
JNJ-64264681
Product
ALTCAR.CD30
Clinical trial
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
Status: Recruiting, Estimated PCD: 2027-07-31
Product
Immune Globulin Infusion
Product
Anti-CD19 CAR T Cells
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2028-07-05
Clinical trial
A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
Status: Active (not recruiting), Estimated PCD: 2011-09-01
Drug
doxorubicin
Clinical trial
A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Status: Terminated, Estimated PCD: 2020-07-17
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System Tumors
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-11-25
Product
JNJ-67856633
Product
SCRI-CAR22v2
Clinical trial
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Siltuximab
Clinical trial
A Cancer Research Phase I/ II Trial of ALETA-001 in Participants Who Do Not Achieve or Maintain an Optimal Response to Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Malignancies
Status: Recruiting, Estimated PCD: 2027-12-01
Product
ALETA-001
Clinical trial
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Product
Autologous CD22 CAR T
Clinical trial
Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups
Status: , Estimated PCD: 2004-05-01
Product
ABVD regimen
Product
BEACOPP regimen
Product
Epirubicin
Clinical trial
Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group
Status: Active (not recruiting), Estimated PCD: 2023-12-15
Product
CHEP
Clinical trial
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Status: Completed, Estimated PCD: 2012-11-01
Product
Dasatinib
Clinical trial
High Dose Chemotherapy and Combination Anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
Screening for Oculocerebral Lymphoma by Identifying the Phenotype Carried by Circulating NK Cells in Patients With Uveitis
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Blood sample
Clinical trial
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
Entinostat
Clinical trial
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
ASTX660
Clinical trial
A Phase II Trial of Ifosfamide, Carboplatin, and Etoposide (ICE) Chemotherapy in Combination With Rituximab as Salvage Therapy
Status: Completed, Estimated PCD: 2004-03-01
Clinical trial
A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-03-22
Product
iC9-CAR19 T cells
Product
AP1903
Drug
carboplatin
Drug
ifosfamide
Clinical trial
BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma
Status: , Estimated PCD: 2010-01-01
Product
BEACOPP
Clinical trial
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Revlimid
Clinical trial
PROSPECTIVE OBSERVATIONAL STUDY FOR THE ASSESSMENT OF CARDIAC DYSFUNCTION INDUCED BY CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY
Status: Not yet recruiting, Estimated PCD: 2024-11-02
Product
Chimeric Antigen Receptor
Clinical trial
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Completed, Estimated PCD: 2020-06-03
Clinical trial
A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Product
Biological/Genetically Modified T cells
Clinical trial
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) Treatment
Status: Active (not recruiting), Estimated PCD: 2023-11-03
Product
Simvastatin
Clinical trial
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
Status: , Estimated PCD: 2022-08-18
Clinical trial
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Ketorolac
Product
Normal saline
Clinical trial
Medical Professor,CHONGQING UNIVERSITY CANCER HOSPITAL
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor
Clinical trial
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Status: Completed, Estimated PCD: 2020-04-23
Drug
IL-2
Product
Carmustine
Product
Cytarabine
Product
Acetaminophen
Product
Oxycodone Acetaminophen
Product
Morphine
Product
Hydrocodone/Acetaminophen
Product
Oxycodone
Clinical trial
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Status: Recruiting, Estimated PCD: 2025-10-21
Product
N-Acetylcysteine
Clinical trial
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
Status: Recruiting, Estimated PCD: 2024-12-28
Drug
Cisplatin
Clinical trial
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-05-07
Product
Polymorphism Analysis
Clinical trial
A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
CPI-613
Clinical trial
Open-label, Randomized Comparative Study to Assess Biosimilar Pegfilgrastim Versus Biosimilar Filgrastim in Patients With Multiple Myeloma and Lymphoma Post Autologous Hematopoietic Stem Cell Transplantation
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
Grastofil®
Product
Lapelga
Clinical trial
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Drug
bendamustine
Clinical trial
First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents
Status: Completed, Estimated PCD: 2023-10-31
Drug
prednisolone
Clinical trial
A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Indolent B Cell Lymphoma
Status: Completed, Estimated PCD: 2002-01-01
Product
Keyhole Limpet Hemocyanin
Drug
sargramostim
Product
Tumor cell-based vaccine
Clinical trial
A Clinical Study to Evaluate the Safety and Effectiveness of CD19-CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-31
Product
CD19-CD22 CAR-T cells
Drug
dacarbazine
Clinical trial
Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease
Status: , Estimated PCD: 2000-05-01
Clinical trial
An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma
Status: Completed, Estimated PCD: 2014-03-01
Clinical trial
A Prospective Multicenter Phase 2 Study of the Chemotherapy-light Combination of Intravenous Rituximab With the Antibody-drug Conjugate Polatuzumab Vedotin and the Bispecific Antibody Glofitamab in Previously Untreated Aggressive B-cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Status: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
Phase Ib Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2021-12-31
Product
Roflumilast
Clinical trial
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders
Status: Active (not recruiting), Estimated PCD: 2007-03-13
Product
Fludarabine phosphate
Drug
methotrexate
Drug
mycophenolate mofetil
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Status: Active (not recruiting), Estimated PCD: 2024-01-30
Product
DA-EPOCH-R
Clinical trial
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Status: Completed, Estimated PCD: 2019-06-07
Product
Rabbit ATG
Clinical trial
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.
Status: Completed, Estimated PCD: 2016-10-01
Product
RCOMP
Product
RCHOP
Clinical trial
Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma
Status: Active (not recruiting), Estimated PCD: 2013-09-01
Product
TGFbeta resistant LMP-specific CTLs
Clinical trial
Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Status: , Estimated PCD: 2023-11-02
Product
BeEAM Regimen
Product
Methotrexate
Clinical trial
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Neratinib
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
Status: Active (not recruiting), Estimated PCD: 2025-04-04
Clinical trial
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-06-01
Drug
PEG-rhG-CSF
Clinical trial
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Status: Active (not recruiting), Estimated PCD: 2028-06-01
Product
Anti-thymocyte globulin
Product
Solumedrol
Product
Mycophenolate mofetil
Clinical trial
Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients With Cancer
Status: , Estimated PCD: 2024-08-01
Drug
18F-FDG
Product
Hyperpolarized [1-13C]Pyruvate
Clinical trial
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2025-01-10
Product
HSCT with TBI Regimen
Clinical trial
Phase II Trial of Zanubrutinib in Primary Cold Agglutinin Disease. CaZa Study
Status: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Prevenar13
Clinical trial
Phase II Multicenter Clinical Trial: Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Status: Recruiting, Estimated PCD: 2027-06-01
Product
Mosunetuzumab
Clinical trial
Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Status: Completed, Estimated PCD: 2022-09-19
Clinical trial
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-11-11
Product
Tagraxofusp
Clinical trial
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma (CTMS# 22-0016)
Status: Withdrawn, Estimated PCD: 2027-01-01
Product
R-Chop and Roflumilast
Product
Hydrocortisone
Clinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Status: Completed, Estimated PCD: 2022-10-20
Product
Enzyme Inhibitor
Clinical trial
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2026-04-06
Product
HSCT
Clinical trial
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-05-09
Clinical trial
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Status: Recruiting, Estimated PCD: 2025-03-10
Product
VIP152
Clinical trial
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Drug
Orelabrutinib
Drug
T-VEC
Drug
mFOLFOX6
Clinical trial
A Phase II Study of Xisomab 3G3, a Monoclonal Antibody Preventing the Activation of FXI by FXIIa, for the Prophylaxis of Catheter-Associated Thrombosis
Status: Terminated, Estimated PCD: 2021-10-05
Product
Xisomab 3G3
Clinical trial
Prospective Comparison Between Prophylactic and On-demand Use of Tocilizumab in CAR-T Recipients - a Randomized, Two Arm, Open-label, Single-center Trial
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2012-10-01
Drug
R-CHOP
Product
Autologous Tumor Cell-Based Vaccine
Drug
interleukin-2
Clinical trial
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Status: Recruiting, Estimated PCD: 2027-11-26
Clinical trial
Clinical Study on the Effectiveness and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells for Lymphoma and Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-01-01
Product
RhG-CSF
Clinical trial
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Status: Active (not recruiting), Estimated PCD: 2021-07-26
Clinical trial
Pilot Trial to Evaluate Immune Response Using Idiotype Vaccines Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Follicular Lymphoma
Status: Terminated, Estimated PCD: 2008-04-03
Product
Autologous Tumor Cell Vaccine
Clinical trial
A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus ICIs for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.
Status: Recruiting, Estimated PCD: 2025-12-30
Product
TP53-EphA-2-CAR-DC
Drug
anti-PD-1 antibody
Product
Anti-CTLA4 Monoclonal Antibody
Drug
busulfan
Product
cyclosporine
Clinical trial
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Ipilimumab
Clinical trial
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Status: Active (not recruiting), Estimated PCD: 2021-01-15
Product
ATLCAR.CD30
Clinical trial
Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Status: Completed, Estimated PCD: 2022-09-13
Product
Adult differentiated autologous T-cells
Clinical trial
An Exploratory Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars in Real-world Practice
Status: Completed, Estimated PCD: 2022-09-30
Product
Granulocyte-Colony Stimulating Factor
Clinical trial
Chidamide Combined With R-GemOx(Rituximab、Gemcitabine Plus Oxaliplatin) Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: a Multi-center, Single Arm, Phase II Study
Status: Completed, Estimated PCD: 2022-11-16
Product
Chidamide
Clinical trial
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2025-08-26
Clinical trial
Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-01
Product
NUC-7738
Clinical trial
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-11-01
Drug
Zanubrutinib
Product
Bendamustin
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Clinical trial
A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine
Status: Active (not recruiting), Estimated PCD: 2025-08-25
Product
Afatinib
Clinical trial
Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
Status: Terminated, Estimated PCD: 2015-07-01
Drug
Docetaxel
Drug
Procarbazine
Clinical trial
A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
Status: Completed, Estimated PCD: 2001-01-01
Clinical trial
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2022-08-02
Clinical trial
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Completed, Estimated PCD: 2020-03-19
Clinical trial
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Status: Active (not recruiting), Estimated PCD: 2022-06-30
Product
Lactobacillus plantarum strain 299
Product
Lactobacillus plantarum strain 299v
Clinical trial
Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Status: Terminated, Estimated PCD: 2011-12-01
Product
Binimetinib
Clinical trial
Phase 1/1b Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell Malignancies
Status: Completed, Estimated PCD: 2019-10-01
Product
CAR-20/19-T cells
Clinical trial
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
An Open-Label Phase Ⅰ/Ⅱ Study of EZH2 Inhibitor SHR2554 in Combination With Anti-PD-L1/TGFβ Antibody SHR1701 in Patients With Advanced or Metastatic Solid Tumors and Relapsed/Refractory B-cell Lymphomas
Status: Recruiting, Estimated PCD: 2024-12-01
Product
SHR2554+SHR1701
Product
SHR1701
Clinical trial
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
TQB2450
Drug
Selinexor
Product
Vinorelbine
Clinical trial
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma
Status: Recruiting, Estimated PCD: 2034-01-31
Drug
AN0025
Product
Capivasertib
Clinical trial
A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma and Multicentric Castleman Disease
Status: Recruiting, Estimated PCD: 2034-08-01
Product
Daratumumab
Clinical trial
Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma
Status: Recruiting, Estimated PCD: 2025-09-10
Product
KL-7SHRNA
Clinical trial
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Product
Selinexor + Lenalidomide + Rituximab
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-02-08
Product
SCRI-huCAR19v1
Product
SCRI-huCAR19v2
Clinical trial
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-02-02
Drug
Vitamin D3
Clinical trial
Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CD19CAT-41BBZ CAR T-cells
Drug
Tocilizumab
Clinical trial
Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin
Status: Completed, Estimated PCD: 2008-02-01
Product
Anti-Thymocyte Globulin
Product
Polymerase Chain Reaction
Clinical trial
An Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2025-03-31
Product
RO7227166
Clinical trial
A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Darzalex Faspro
Clinical trial
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2024-03-08
Product
Anti-CD19-chimeric-antigen-receptor-transduced T cells
Clinical trial
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory NHL or CLL
Status: Recruiting, Estimated PCD: 2027-12-01
Drug
ONO-7018
Clinical trial
Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL
Status: Recruiting, Estimated PCD: 2025-04-14
Clinical trial
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Completed, Estimated PCD: 2010-09-01
Drug
dexamethasone
Clinical trial
A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma
Status: Completed, Estimated PCD: 2002-01-01
Product
Tumor cell-based vaccine therapy
Drug
FOLFOXIRI
Clinical trial
A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2016-01-31
Clinical trial
A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma
Status: Completed, Estimated PCD: 2002-01-01
Drug
Allopurinol
Clinical trial
A Phase I Study of AT7519M Given Twice Weekly in Patients With Advanced Incurable Malignancy
Status: Completed, Estimated PCD: 2012-03-13
Product
CDKI AT7519
Clinical trial
Pilot Study on the Reduced Intravenous Fluids to Improve Clearance of High-Dose Methotrexate (HDMTX) in Children With Lymphoma or Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2022-12-07
Product
Intravenous fluids
Clinical trial
A Study of the Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2027-12-30
Product
Zanubrutinib,Obinutuzumab
Clinical trial
A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies
Status: Completed, Estimated PCD: 2023-09-30
Product
CAR-37
Clinical trial
A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician's Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-12-06
Product
Bortezomib
Clinical trial
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: , Estimated PCD: 2002-02-01
Product
nicotine
Clinical trial
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Completed, Estimated PCD: 2022-06-30
Product
Mitoxantrone
Product
Zanubrutinib and R-BAC
Clinical trial
Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Induction Phase1
Product
Induction
Product
M
Product
Maintenance Therapy
Product
Reinduction Phase 1
Product
Reinduction
Product
Intrathecal
Clinical trial
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Status: Active (not recruiting), Estimated PCD: 2024-12-02
Clinical trial
Retreatment With CTL019/CTL119 in Patients With Late Relapse of B-Cell Lymphomas
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
CD19 redirected autologous T cells
Clinical trial
A Phase II Study of Bortezomib and Gemcitabine in Patients With Relapsed Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2009-04-21
Clinical trial
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2028-04-19
Drug
pembrolizumab
Product
Favezelimab
Clinical trial
CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2021-03-08
Product
DLI
Clinical trial
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)
Status: Terminated, Estimated PCD: 2015-04-09
Clinical trial
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Status: Completed, Estimated PCD: 2023-07-17
Product
ALRN-6924
Clinical trial
Phase I/II Study of CD70 Targeted CAR-T Cell Treatment in CD70 Positive Relapsed/Refractory Lymphoma
Status: Recruiting, Estimated PCD: 2025-12-31
Product
CD70-targeting CAR-T cells
Clinical trial
A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment
Status: Completed, Estimated PCD: 2011-04-01
Clinical trial
A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2005-07-21
Clinical trial
Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.
Status: Terminated, Estimated PCD: 2014-06-20
Clinical trial
Strategy Therapy on Early Phase Cancer Therapeutics-Related Cardiac Dysfunction Patients
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Prevention therapy
Product
Rescue therapy
Clinical trial
Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study
Status: Completed, Estimated PCD: 2020-04-01
Product
AFM13
Clinical trial
Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab vs Observation
Status: Completed, Estimated PCD: 2013-07-29
Drug
Ketamine
Clinical trial
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms
Status: Completed, Estimated PCD: 2012-04-01
Drug
bevacizumab
Drug
vinca alkaloids
Clinical trial
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Ruxolitinib
Clinical trial
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Status: Recruiting, Estimated PCD: 2025-03-31
Product
VIC- 1911
Clinical trial
A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma
Status: , Estimated PCD: 2006-08-01
Product
Denileukin Diftitox
Clinical trial
T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Status: Completed, Estimated PCD: 2018-06-12
Product
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Clinical trial
AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial
Status: Withdrawn, Estimated PCD: 2023-04-18
Product
Carvedilol
Product
Lisinopril
Product
Pravastatin
Product
Spironolactone
Clinical trial
A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2022-03-30
Product
High dose chemotherapy before allogeneic stem cell transplantation
Clinical trial
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Status: Active (not recruiting), Estimated PCD: 2020-11-30
Product
EPOCH
Clinical trial
Pembrolizumab and Radiotherapy for Previously Untreated Patients With Limited Stage NK/T Cell Lymphoma Who Are Not Eligible to Chemotherapy
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab
Status: Completed, Estimated PCD: 2012-11-14
Clinical trial
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Status: Completed, Estimated PCD: 2021-11-06
Drug
Tislelizumab Injection
Clinical trial
Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Clinical Study on the Effectiveness and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor Injection and PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma.
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.
Status: Withdrawn, Estimated PCD: 2022-03-04
Product
BMS-986414
Product
BMS-986413
Clinical trial
Vaccine Responses in Patients With B Cell Malignancies
Status: Recruiting, Estimated PCD: 2024-08-16
Product
Fluzone
Product
Shingrix
Product
Flucelvax
Product
Afluria
Product
Prevnar 13
Product
Heplisav
Product
Pfizer-COVID-19 Vaccine
Product
FluLaval
Product
Fluarix
Product
PNEUMOVAX 23
Product
Prevnar 20
Product
AREXVY
Clinical trial
A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen
Status: Terminated, Estimated PCD: 2010-06-01
Product
Sodium thiosulfate
Clinical trial
A Real-world Study: Efficacy and Safety of Selinexor-based Regimens for Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-10
Clinical trial
Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas
Status: Completed, Estimated PCD: 2018-05-30
Clinical trial
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
Preventive and Personalized Medicine (2021-2023)
Status: Completed, Estimated PCD: 2023-01-20
Product
SNP analysis
Clinical trial
Umbilical Cord Blood Transplantation From Unrelated Donors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2019-08-21
Product
CD45RA-depleted peripheral blood mononuclear cells
Clinical trial
A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma
Status: , Estimated PCD: 2003-04-01
Product
Pegylated Liposomal Doxorubicin
Clinical trial
A Single-Center, Open-Label Study to Evaluate the Safety and Efficacy of Nipent, Cytoxan, and Rituxan ("PCR") in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma or Bulky Lymphoma
Status: Completed, Estimated PCD: 2014-12-01
Product
Nipent
Clinical trial
Efficacy and Safety of Plerixafor in Patients With Poorly Mobilized Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-20
Product
Plerixafor,G-CSF
Clinical trial
German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure
Status: Completed, Estimated PCD: 2008-04-01
Product
Alemtuzumab
Product
Cladribine
Clinical trial
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Status: Terminated, Estimated PCD: 2022-01-14
Product
RNA analysis
Product
Gene Expression Analysis
Product
Polymorphism analysis
Clinical trial
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Valemetostat
Clinical trial
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-03-23
Product
PU-H71
Clinical trial
The Efficacy and Safety of L-DEP Regimen Combined With PD-1 Antibody an Induction Therapy for Epstein-Barr Virus (EBV)-Positive Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Product
L-DEP and PD-1 antibody
Clinical trial
A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
Status: Terminated, Estimated PCD: 2021-12-09
Product
SYNB1891
Clinical trial
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Lutetium Lu 177-Edotreotide
Clinical trial
A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Axicabtagene Ciloleucel
Clinical trial
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
Status: Terminated, Estimated PCD: 2009-03-01
Clinical trial
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Completed, Estimated PCD: 2011-09-01
Clinical trial
An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-11-15
Product
BTCT4465A
Clinical trial
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy
Status: Terminated, Estimated PCD: 2021-09-01
Product
Genistein
Clinical trial
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilgrastim for Neutrophil Recovery After Autologous Stem Cell Transplant
Status: Completed, Estimated PCD: 2023-02-25
Clinical trial
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL Trial)
Status: Active (not recruiting), Estimated PCD: 2023-02-28
Product
Nebivolol
Clinical trial
Clinical Study of the Efficacy and Safety of Chimeric Antigen Receptor T-cell Therapy Following Autologous Stem Cell Transplantation for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2027-01-01
Product
CAR-T Cell Therapy
Clinical trial
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2021-06-09
Product
EPOCH-R
Product
Idiotype vaccine
Clinical trial
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Retifanlimab
Clinical trial
Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
CUDC-907
Clinical trial
Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
Ofatumumab
Clinical trial
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers
Status: Completed, Estimated PCD: 2019-06-20
Product
rh IL-15
Clinical trial
An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
Status: , Estimated PCD: 2041-12-01
Product
Allogeneic CAR-T
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Product
Romidepsin
Clinical trial
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2020-08-22
Product
Vincristine sulfate liposome
Clinical trial
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Status: Completed, Estimated PCD: 2019-12-02
Clinical trial
A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2024-05-03
Drug
Lurbinectedin
Clinical trial
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Inotuzumab Ozogamicin
Clinical trial
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Status: Recruiting, Estimated PCD: 2025-07-31
Product
PCV20
Clinical trial
IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL
Status: Active (not recruiting), Estimated PCD: 2021-11-07
Product
CD56-Enriched Donor Lymphocyte Infusion
Clinical trial
A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
Tafasitamab
Clinical trial
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Completed, Estimated PCD: 2016-01-01
Clinical trial
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Status: Recruiting, Estimated PCD: 2033-06-27
Clinical trial
A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies
Status: Recruiting, Estimated PCD: 2028-12-30
Product
Anti-CD19 and anti-CD20 bicistronic CAR T- cells
Clinical trial
Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas
Status: Not yet recruiting, Estimated PCD: 2027-10-01
Drug
Epcoritamab
Clinical trial
A Single Arm, Open-labelled Phase II Clinical Trial of Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) for Treatment of B-cell Haematological Malignancies
Status: Recruiting, Estimated PCD: 2026-12-31
Product
CUCART19
Clinical trial
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-01-31
Product
R-CHOEP
Drug
DA-EPOCH-R
Clinical trial
Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma
Status: Terminated, Estimated PCD: 2021-07-27
Product
Avelumab
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Status: Recruiting, Estimated PCD: 2027-10-29
Product
JNJ-88998377
Clinical trial
A Pilot Study of Pembrolizumab in Combination With Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Product
TMZ